M14-431/ M14-433/ M14-430

Magnifier Icon Suche

Titel der Studie:

Titel:

  • M14-431: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy
     
  • M14-433: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies
     
  • M14-430: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433 

 

Studiencode:
M14-431/ M14-433/ M14-430

EUDRACT-Nr.:
2017-001226-18

2017-001240-35

2017-001225-41


M14-431: https://clinicaltrials.gov/ct2/show/NCT03345836 

M14-433: https://clinicaltrials.gov/ct2/show/NCT03345849 

M14-430: https://clinicaltrials.gov/ct2/show/NCT03345823 

 
Für weitere Informationen nehmen Sie bitte Kontakt mit unserem Studienzentrum auf.

 

Ansprechpartner im Studienzentrum Halle:

  • PD Dr. med. Jens Walldorf 
  • Dr. med. Robin Greinert

 


Kontakt:
Klinisches Studienzentrum
Universitätsklinik und Poliklinik für Innere Medizin I 
Martin-Luther-Universität Halle-Wittenberg /
Universitätsklinikum Halle (Saale) 
Ernst-Grube-Straße 40
06120 Halle

Telefon: 0345 557 2668
Telefax: 0345 557 2253
email: studienzentrummedizin.uni-hallede